1 / 37

Obstructive airways disease

Obstructive airways disease . COPD Asthma Gordon Christie Consultant Respiratory Physician ARI. Objectives. Diagnosis & assessment of severity Appropriate investigation When to refer Empirical treatment Chronic disease Acute exacerbations. Asthma. COPD. What is it?.

albert
Download Presentation

Obstructive airways disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Obstructive airways disease COPD Asthma Gordon Christie Consultant Respiratory Physician ARI

  2. Objectives • Diagnosis & assessment of severity • Appropriate investigation • When to refer • Empirical treatment • Chronic disease • Acute exacerbations

  3. Asthma COPD What is it? • No truly satisfactory definition • Reversible airflow limitation • Bronchial hyperreactivity • Eosinophilic airflow inflammation • Better defined • Irreversible airflow obstruction • Gradually progressive • Inflammation • Usually smoking associated

  4. Emphysema (Pathology) Chronic Bronchitis (Symptoms) COPD (Fixed airflow obstruction) Asthma (Reversible Airflow obstruction)

  5. Epidemiology • Asthma • Point prevalence ~8-10% in children, 5% in adults • Severe disease much less common • Complex genetic-environmental interaction • COPD • Point prevalence 1.5-2% • Much undiagnosed symptomatic disease • Much asymptomatic airflow limitation (?5-8% of adult population)

  6. COPD: Causation • In the UK • Overwhelmingly cigarette smoking • Dose response relationship to smoking exposure • Rare under 20 pack years • Occupational dust exposure of minor (& declining) importance • Some individuals at high genetic risk • Alpha 1 antitrypsin deficiency • Rare familial susceptibility • Passive smoking of minor importance

  7. Impact on NHS Grampian • Catchment population 560,000 (~1% of UK) • Relatively low deprivation

  8. Making a diagnosis • Asthma • Common at all ages • Usually mild • Usually variable symptoms • Characterised by exacerbations • May well be undiagnosed • Usually frequent “chest infections” or “bronchitis” • Smokers get pure asthma too ! • But may not respond to inhaled steroid nearly as well

  9. COPD • Predominantly a disease of older adults • Rare under 40 • Uncommon under 50 • Strong dose response relationship to smoking exposure • Uncommon under 20 pack years

  10. Assessing the breathless patient • Is there an existing diagnosis? • Is it right?? • How breathless? • MRC1:Breathless on significant exertion • MRC2:Breathless on moderate exertion • MRC3: Breathless walking with own age • MRC4: Breathless on minimal exertion • MRC5: Breathless at rest

  11. History • Duration of breathlessness • COPD long history, gradually progressive; may require careful history taking to elicit • Asthma classically symptom variability • Often associated with triggers • Nocturnal symptoms • Exacerbations: markers of severity/ instability • Childhood symptoms/ school absence • Often recurrent “bronchitis” or “pneumonia”

  12. Investigations • Oximetry...hypoxaemia is bad • Spirometry • Fundamental • If normal suspect asthma • Peak flow • Need to seek variability over time (at least 2 weeks) • More detailed pulmonary function • Gas transfer • 6 minute walk • Chest X ray • Primarily to exclude other diagnoses (LVF, ILD etc)

  13. Severe airflow obstruction Normal (young, tall, male) Spirometry

  14. Peak flow variability

  15. Peak flow • Test for asthma • Need 2 weeks or more recorded • First 3-4 days can usually be discarded (practice effect) • Look for 20% variability • Some variability is physiological • Look for morning dips & dips with symptomatic periods • Useful with trial of treatment • But remember timescale of treatment effect

  16. Pulmonary function testing • Main test of discriminant value is gas transfer • Measure of lung parenchymal function • Reduced (usually significantly <50% predicted) in significant COPD • Correlates with disease severity • Normal or supranormal in asthma • Functional tests: primarily assess severity • 6 minute walk • Desaturation is ominous • Shuttle walk • Formal cardiopulmonary exercise testing • Limited availability

  17. Other tests • CXR: Primarily to exclude obvious LVF, ILD etc. • NOT a diagnostic test for airway disease! • ECG: Primarily to exclude IHD but remember RV changes • Echocardiography • Remember PA pressure/ RV hypertrophy & dilatation • HRCT • Can be helpful assessing structural emphysema (normally unnecessary as diagnosis already made) • Invaluable in assessment of interstitial lung disease

  18. Making a diagnosis:COPD • Symptoms • Exacerbations • Smoking history • Signs of hyperinflation clinically if severe • Spirometry confirms obstruction & correlates with severity • Significant function limitation <50% predicted • Often housebound <1 litre absolute FEV1 • Gas transfer may help if uncertain • Beware pulmonary hypertension if advanced disease • May merit echo, 6 minute walk • HRCT rarely necessary

  19. Making a diagnosis: Asthma • Variable exertional breathlessness • Childhood & family history common • History of precipitants (exercise, cats, cold, pollen, paint, perfume) • Associated atopy (hayfever, eczema) • Peripheral blood eosinophilia, raised total & specific IgE • Persistent symptoms (cough, sputum, wheeze) imply poor control • Usually no signs on examination & normal spirometry • Peak flow variability common, trial of treatment useful • Sometimes chronic airflow limitation indistinguishable from COPD but exercise tolerance better than expected from spirometry & gas transfer preserved

  20. When to refer • Early! (..the drugs take time to work) • Concurrent with trial of empirical treatment • Concurrent with requests for additional straightforward tests (pulmonary function, echo primarily) • If real diagnostic doubt • Poorly controlled disease (persistent symptoms, frequent exacerbations) • Advanced disease • COPD with low absolute FEV1, evidence of right heart failure • Asthma with significant fixed airflow limitation

  21. When to treat empirically • Majority of situations • If convincing history & evidence of airflow obstruction • Response to treatment often helpful in secondary assessment • With monitoring of outcomes (peak flow chart, review with repeat spirometry), usually after 6-8 weeks treatment

  22. Empirical treatment • Should be designed to achieve rapid results in context of preassessment • Drugs are (generally) safe in short term at high doses • Mainstay is inhaled corticosteroid (beclometasone, budesonide, fluticasone) • Usually combined with long acting beta2 agonist (salmeterol, formoterol) • Bronchodilator for symptom relief • Salbutamol, terbutaline

  23. Inhalers made eas(ier).. • Traditional pressurised MDIs... • Deliver 10-15% dose to the lungs • Delivered dose doubled by spacers • Are difficult to use-require coordination & timing • Doses changing with CFC free inhalers • Deposition patterns may change with CFC inhalers (smaller inhaled particles) • Breath actuated devices (easibreathe etc.) • Much liked by health economists extrapolating from RCTs, less favoured by patients & their doctors

  24. Dry powder inhalers • Better drug deposition (up to 30-35% delivered dose) • Simpler to use (no requirement for timing) • Effective even at low peak inspiratory flow • Often preferred by patients • Better range of combination inhaled steroid/ LABA products available

  25. Practical empirical treatment • Start reliever bronchodilator (usually salbutamol 200mcg as required) • Start combined ICS/LABA • Seretide (50-100-125-250-500 mcg fluticasone; 50mcg salmeterol) • Symbicort (100-200-400 mcg budesonide; 6-12 mcg formoterol) • Monitor outcomes • Peak flow (if asthma) • Clinical review with repeat spirometry in 6-8 weeks

  26. Treatment: COPD • COPD • Recent trials • TORCH (COPD, FEV1<60% predicted; RCT, n=6000, placebo vs fluticasone 500 mcg bd alone vs salmeterol 50 mcg bd vs combined fluticasone 500mcg-salmeterol 50mcg bd over 3 years) • Exacerbations, lung function & quality of life all improved with all active teatment • Lung function improved with combination, salmeterol alone • Effects of combination treatment additive compared to single drugs alone • Borderline effect on mortality (p=0.052!) • Combination probably represents current standard of care • Some concern about increased incidence of pneumonia over 3 year followup

  27. COPD: Drug choices • INSPIRE: ICS/LABA vs Tiotropium (long acting anticholinergic bronchodilator) • Both improved quality of life, lung function, reduced exacerbations • Combination superior to tiotropium • Cochrane review suggests combination treatment does not have mortality benefit • Clear benefits in exacerbation frequency (down 30-40%), quality of life & lung function (although latter are modest) • UPLIFT: Tiotropium vs placebo • Reduction in exacerbation frequency & improved quality of life • No mortality benefit (P=0.09) • Increased rate of vascular death reported in US meta analysis of anticholinergic treatment in COPD (but not UPLIFT) • No trials of combination ICS/LABA/long acting anticholinergic

  28. Other drugs • Mucolytics • 2 good trials (BRONCUS, PEACE) suggesting reduced exacerbation frequency in inhaled steroid naive only • Much cheaper & relevant in resource poor settings, less so in UK • Theophylline • Few good trials but extensively used • Probably safer than was believed used at low doses; no need to chase “therapeutic” drug levels • Narrow therapeutic index • “Boutique” theophyllines (rofilumilast, cilomilast on horizon)-unclear if additional benefit justifies expense • Nebulisers • Inefficient-delivered drug dose usually ~5% • Useful acutely • Not for maintenance treatment

  29. Pulmonary rehabilitation • Usually physiotherapist led • 10 week course, twice weekly sessions • Variety of programmes but usually • Exercise (circuits, upper body) • Breathing control, pacing • Education/ anticipatory care • Smoking cessation • Impressive effects • Significant improvement in exercise function • Improvement in quality of life (greater than drug effects) • Shorter readmissions (though not necessarily fewer) • Developing interest in “acute” pulmonary rehabilitation around acute exacerbations

  30. ..so what do I do? • ENCOURAGE SMOKING CESSATION! • Brief advice • Refer to local service • Bronchodilator for symptom relief • Combined inhaled steroid/ long acting bronchodilator • Currently Seretide 500 bd via dry powder device (accuhaler) for simplicity & concordance • Probably a class effect • Tiotropium • Low dose theophylline (200mg bd) as next step • Refer for pulmonary rehabilitation (where available)

  31. Treatment: Asthma • Empirical treatment: • Step 1: Bronchodilator only • Step 2: Bronchodilator & regular inhaled steroid • Step 3: Add LABA (in practice combination inhalers, as in COPD) or theophylline or leukotriene receptor antagonist • Step 4: Maximise inhaled steroid • Step 5: Add regular oral steroid

  32. Empirical treatment • Depends on previous treatment step & current symptoms • Aiming for good perioperative control • Increase to BTS 3-4 if concerned • Will usually take 2-4 weeks to see effect of additional drug & 6-8 weeks to see effect of increased inhaled steroid • GOAL study suggests that benefit of increasing ICS continues to increase over up to 12 months

  33. Asthma: Other issues • Treat nasal symptoms aggressively if present (“one airway”) in addition to lower airway • Nasal steroid • Leukotriene receptor antagonists • Antihistamines • Gastro oesophageal reflux also worth treating vigorously

  34. Acute exacerbations • Asthma • Oxygen • Nebulised bronchodilators, add ipratropium if severe • IV then Oral steroid (~0.5mg/kg; usually 30-40mg/ day) • Consider magnesium, possibly repeat if severe • Consider IV aminophylline • Antibiotics rarely indicated, some evidence of macrolides

  35. Acute exacerbations • COPD • Oxygen (controlled!) • Nebulised bronchodilators • Reasonable evidence for oral steroid • Appropriate antibiotics • Consider aminophylline • NIV....

  36. NIV • Good evidence for mortality benefit in acute exacerbations with hypercarbia • Widely available; can be used in ward setting • Preferable to intubation in many circumstances • Provides ventilatory support while other treatment works • Not (routinely) for hypoxic respiratory failure in most circumstances

  37. Summary • Diagnosis & assessment of severity • Appropriate investigation • Empirical treatment • Chronic disease • Acute exacerbations • When to refer

More Related